National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 5) (PB 51 of 2018) (Cth)
PB 51 of 2018
National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 5)
National Health Act 1953
___________________________________________________________________________
I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.
Dated 29 June 2018
LISA LA RANCE
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
___________________________________________________________________________
Name of Instrument
(1)This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 5).
(2)This Instrument may also be cited as PB 51 of 2018.
Commencement
This Instrument commences on 1 July 2018.
Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)
Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).
Schedule 1 Amendments
Schedule 1, entry for Amlodipine
(a)omit from the column headed “Form”: Tablet 5 mg (as besylate)
substitute: Tablet 5 mg (as besilate)
(b)omit from the column headed “Form”: Tablet 10 mg (as besylate)
substitute: Tablet 10 mg (as besilate)
Schedule 1, entry for Amlodipine with atorvastatin
(a)omit from the column headed “Form”: Tablet 5 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium)
substitute: Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium)
(b)omit from the column headed “Form”: Tablet 5 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium)
substitute: Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)
(c)omit from the column headed “Form”: Tablet 10 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium)
substitute: Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium)
(d)omit from the column headed “Form”: Tablet 10 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium)
substitute: Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium)
(e)omit from the column headed “Form”: Tablet 10 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium)
substitute: Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium)
(f)omit from the column headed “Form”: Tablet 10 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium)
substitute: Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)
Schedule 1, entry for Amoxycillin
omit from the column headed “Listed Drug”: Amoxycillin substitute: Amoxicillin
Schedule 1, entry for Amoxycillin with Clavulanic Acid
(a)omit from the column headed “Listed Drug”: Amoxycillin with Clavulanic Acid substitute: Amoxicillin with Clavulanic Acid
(b) omit from the column headed “Form”: Powder for oral suspension containing 400 mg amoxycillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL substitute: Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL (c) omit from the column headed “Form”: Tablet containing 500 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) substitute: Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) (d) omit from the column headed “Form”: Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) substitute: Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)
Schedule 1, entry for Cephalexin
(a)omit from the column headed “Listed Drug”: Cephalexin substitute: Cefalexin
(b)omit from the column headed “Form”: Capsule 250 mg (anhydrous)
substitute: Capsule 250 mg (as monohydrate)
(c)omit from the column headed “Form”: Capsule 500 mg (anhydrous)
substitute: Capsule 500 mg (as monohydrate)
(d)omit from the column headed “Form”: Granules for oral suspension 125 mg per 5 mL, 100 mL
substitute: Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL
(e)omit from the column headed “Form”: Granules for oral suspension 250 mg per 5 mL, 100 mL
substitute: Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL
Schedule 1, entry for Eprosartan
(a)omit from the column headed “Form”: Tablet 400 mg (as mesylate)
substitute: Tablet 400 mg (as mesilate)
(b)omit from the column headed “Form”: Tablet 600 mg (as mesylate)
substitute: Tablet 600 mg (as mesilate)
Schedule 1, entry for Frusemide
omit from the column headed “Listed Drug”: Frusemide substitute: Furosemide
Schedule 1, omit entry for Glipizide
Schedule 1, entry for Indomethacin
omit from the column headed “Listed Drug”: Indomethacin substitute: Indometacin
Schedule 1, entry for Levonorgestrel with Ethinyloestradiol
omit from the column headed “Listed Drug”: Levonorgestrel with Ethinyloestradiol substitute: Levonorgestrel with Ethinylestradiol
Schedule 1, after entry for Levonorgestrel with Ethinylestradiol
insert:
| Levothyroxine | Tablet containing 50 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 13.71 | 15.49 |
| Tablet containing 75 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 14.23 | 16.07 | |
| Tablet containing 100 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 14.20 | 15.99 | |
| Tablet containing 200 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 16.65 | 18.44 |
Schedule 1, entry for Norethisterone with Ethinyloestradiol
omit from the column headed “Listed Drug”: Norethisterone with Ethinyloestradiol substitute: Norethisterone with Ethinylestradiol
Schedule 1, entry for Perindopril with amlodipine
(a)omit from the column headed “Form”: Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besylate)
substitute: Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate)
(b)omit from the column headed “Form”: Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besylate)
substitute: Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate)
(c)omit from the column headed “Form”: Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besylate)
substitute: Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate)
(d)omit from the column headed “Form”: Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besylate)
substitute: Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate)
Schedule 1, entry for Telmisartan with Amlodipine
(a)omit from the column headed “Form”: Tablet 40 mg-5 mg (as besylate)
substitute: Tablet 40 mg-5 mg (as besilate)
(b)omit from the column headed “Form”: Tablet 40 mg-10 mg (as besylate)
substitute: Tablet 40 mg-10 mg (as besilate)
(c)omit from the column headed “Form”: Tablet 80 mg-5 mg (as besylate)
substitute: Tablet 80 mg-5 mg (as besilate)
(d)omit from the column headed “Form”: Tablet 80 mg-10 mg (as besylate)
substitute: Tablet 80 mg-10 mg (as besilate)
Schedule 1, omit entry for Thyroxine
Schedule 2, entry for Amoxycillin
omit from the column headed “Listed Drug”: Amoxycillin substitute: Amoxicillin
Schedule 2, entry for Eprosartan
(a)omit from the column headed “Form”: Tablet 400 mg (as mesylate)
substitute: Tablet 400 mg (as mesilate)
(b)omit from the column headed “Form”: Tablet 600 mg (as mesylate)
substitute: Tablet 600 mg (as mesilate)
0
0
0